RoActemra Could Change The Current Standard Of Treatment For People Living With Rheumatoid Arthritis

Main Category: Arthritis / Rheumatology
Also Included In: Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 28 May 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article

Patient / Public:not yet rated

Healthcare Prof:not yet rated

Roche announced new data from the ACT-RAY study, presented at the European League Against Rheumatism congress. The results demonstrated that in people with rheumatoid arthritis (RA), RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) alone had comparable clinical efficacy to RoACTEMRA plus methotrexate (MTX). The safety profile of RoACTEMRA was consistent with previous clinical trials.

Methotrexate, a disease modifying anti-rheumatic drug (DMARD), is widely prescribed for people with RA. However, up to 40% of people given MTX do not adequately respond to treatment or experience adverse events and require other drugs to help control their inflammation. Data from the ACT-RAY study demonstrated that RoACTEMRA provided clinical benefit, regardless of whether it was given in combination with MTX or as a monotherapy.1

“The findings of the ACT-RAY study provide further evidence of the meaningful benefits of RoActemra monotherapy. RoActemra is approved for people with rheumatoid arthritis who do not respond to, or are unable to tolerate the side effects associated with methotrexate, a commonly used treatment for the disease,” said Hal Barron, M.D., Head of Global Development and Chief Medical Officer for Roche.
RA is a chronic, progressive inflammatory disease of the joints and surrounding tissues that is
associated with intense pain, irreversible joint destruction and systemic complications such
as fatigue and anaemia. RoACTEMRA is the first in a new class of treatments for rheumatoid
arthritis which target interleukin-6 receptors. It is currently approved in Europe for the
treatment of RA in people who have either responded inadequately to, or who were intolerant
to, previous therapy with one or more DMARDs or tumour necrosis factor (TNF) inhibitors.
Results from the ACT-RAY study build on a previous Phase III study (AMBITION) which
showed that compared to MTX, patients receiving RoACTEMRA alone achieved a greater
reduction of signs and symptoms of RA (e.g. swollen and tender joints) at six months and
nearly three times as many patients achieved DAS28 disease remission. RoACTEMRA is
the first and only biologic to have demonstrated superiority as monotherapy treatment over


ACT-RAY is a Phase IIIb double-blind two year study designed to evaluate the efficacy and safety
of adding RoACTEMRA to MTX versus switching from MTX to RoACTEMRA monotherapy in MTX inadequate responder (IR), biologic naïve, adult patients with moderate to severe active RA.
556 patients with inadequate response to MTX received RoACTEMRA (8mg/kg every four weeks)
and were randomised to either remain on stable dose of MTX (combination therapy, n=279), or
receive a matching dose of placebo (monotherapy, n=277) with 92 percent (n=512) completing
the initial 24 week period. The primary endpoint of this study was to achieve DAS28 remission

Results (at week 24) showed that RoACTEMRA monotherapy had comparable clinical efficacy to
RoACTEMRA with MTX in RA patients who had an inadequate response to MTX.

— Remission rates were consistent with previous clinical studies. DAS28 remission rate
was 35 percent for RoACTEMRA plus placebo and 40 percent for RoACTEMRA plus MTX
(p=0.19; 95% CI -2.4%, 13.7%).

— The fast onset of action of RoACTEMRA was maintained. 18.1 percent and 15.2
percent of patients achieved remission at week eight in the combination and monotherapy
groups respectively.

— No overt differences in the safety profile were observed between the two treatments.
Rates of adverse events, serious adverse events and serious infections per 100 patient
years were 491, 21 and 6 for RoACTEMRA plus MTX and 467, 18 and 6 for RoACTEMRA
plus placebo.


RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) is the result of research
collaboration by Chugai and is also being co-developed globally with Chugai. RoACTEMRA is the
first humanised interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody. ACTEMRA was first
approved in Japan, and launched by Chugai in June 2005 as a therapy for Castleman’s disease;
in April 2008, additional indications for rheumatoid arthritis (RA), polyarticular juvenile idiopathic
arthritis (pJIA) and systemic-onset juvenile idiopathic arthritis (sJIA) were also approved in Japan.
RoACTEMRA was approved in the European Union in January 2009 for the treatment of RA in
patients who have either responded inadequately to, or who were intolerant to, previous therapy
with one or more disease modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor
(TNF) inhibitors. It is also approved for use in over 90 other countries, including India, Brazil,
Switzerland, and Australia. ACTEMRA was approved in the United States in January 2010 for the
treatment of adult patients with moderately to severely active RA who have had an inadequate
response to one or more TNF inhibitors. In addition, ACTEMRA is now approved in the United
States and Mexico for the treatment of active SJIA in patients two years of age and older.
The safety and efficacy of RoACTEMRA in RA has been established in an extensive clinical
development program including five Phase III clinical studies that enrolled more than 4,000
people with RA in 41 countries, including the United States. The overall safety profile of
RoACTEMRA is consistent across all global clinical studies. The serious adverse events reported
in RoACTEMRA clinical studies include serious infections, gastrointestinal perforations and
hypersensitivity reactions including anaphylaxis. The most common adverse events reported in
clinical studies were upper respiratory tract infection, nasopharyngitis, headache, hypertension
and increased ALT. Increases in liver enzymes (ALT and AST) were seen in some patients; these
increases were generally mild and reversible. Laboratory changes, including increases in lipids
(total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen
in some patients. Treatments that suppress the immune system, such as RoACTEMRA, may
cause an increase in the risk of malignancies.

Source: Roche

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Arthritis / Rheumatology headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top

Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.